In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 589-596

  Klopper, Joshua P ^a,b   Berenz, Andrew ^a   Hays, William R ^a   Sharma, Vibha ^a   Pugazhenthi, Umarani ^a   Janssen, Jennifer ^a   Singh, Meenakshi ^a   Bissonnette, Reid P ^c   Haugen, Bryan R ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN LIKE PROTEIN 4; BEXAROTENE; MESSENGER RNA; PROTEIN; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38949215489     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0269     Document Type: Article

References (29)

1. Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119-28.
2. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-64.
3. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15:78-83.
4. Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol 1999;16:42-9.
5. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587-94.
6. Haugen BR, Larson LL, Pugazhenthi U, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 2004;89:272-80.
7. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
8. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 2004;3:1011-20.
9. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J. Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother 2006;7:907-15.
10. Rigas JR, Dragnev KH. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 2005;10:22-33.
11. Govindan R, Crowley J, Schwartzberg L, et al. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. J Clin Oncol 2006;24:4848-54.
12. Schmutzler C, Hoang-Vu C, Ruger B, Kohrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol 2004;150:547-56.
13. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004;27:334-9.
14. Soignet SL, Miller VA, Pfister DG, et al. Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550). Clin Cancer Res 2000;6:1731-5.
15. Takiyama Y, Miyokawa N, Sugawara A, et al. Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas. J Clin Endocrinol Metab 2004;89:5851-61.
16. Liu YY, Stokkel MP, Pereira AM, et al. Bexarotene increases uptake of radioiodide inmetastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006;154:525-31.
17. Fu J, Ding Y, Huang D, Li H, Chen X. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer. Cancer Lett 2006;248:153-63.
18. Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer 2006;94:654-60.
19. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006;354:2463-72.
20. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005;24:6646-56.
21. Jarzab B, Wiench M, Fujarewicz K, et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 2005;65:1587-97.
22. Chevillard S, Ugolin N, Vielh P, et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 2004;10:6586-97.
23. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006;66:4952-60.
24. Tsai CJ, Herrera-Goepfert R, Tibshirani RJ, et al. Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy. Cancer Epidemiol Biomarkers Prev 2006;15:272-80.
25. Le JS, Amy C, Cazes A, et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003;162:1521-8.
26. Ito Y, Oike Y, Yasunaga K, et al. Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. Cancer Res 2003;63:6651-7.
27. Arao T, Yanagihara K, Takigahira M, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 2006;118:483-9.
28. Galaup A, Cazes A, Le JS, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci U S A 2006;103:18721-6.
29. Masters JR, Thompson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard forhuman cell lines. Proc Natl Acad Sci U S A 2001;98:8012-7.